ä»åã¯
å°æ¹Ÿã®è±
5æ29æ¥ (å)
ãåããž ã¯ã¯ãã³ Q&A 2åç®ã®äºçŽæ¥ B01150å
é¢ããŒããŒ æ¥æ¬å°æ¹Ÿã«ã¯ã¯ãã³æ¯æŽ æ ª
æ¥æã«ãæ
äžæ¥
廿æ¥
ã³ã©ã€ãã
å®ãã
ä¿éºæ
æ¥æ¬æ¿åºããæ°åã³ãããŠã€ã«ã¹ã®æææ¡å€§ã§ã¯ã¯
ãã³ã®ç¢ºä¿ãæ¥åãšãªã£ãŠããè±æç·çµ±çããå°æ¹Ÿ
ã«å¯Ÿããåœå
äŸçµŠçšã«èª¿éããè±è£œè¬å€§æãã¢ã¹ãã©
ãŒãã«ãã®ã¯ã¯ãã³ã®äžéšãæäŸããæ¹åã§æ€èšããŠ
ããããšãåãã£ããäžåœã®åŠšå®³å·¥äœãææããããª
ããã«æ·±ãŸããæ¥å°ã®çµã
æ ªã®åœ±é¿ãææãæ¥æ¡å€§ 倧ããªåé¡ã«ãªã£ãŠã ããŠããããå瀟ãšå¥çŽ
ã¯ããš
ãæ±æ¥æ¬å€§éçœ(20
11幎3æ)ã§ã¯ãå°æ¹Ÿ
ããå€å€§ãªã矩æŽé (2
00åå以äž)ãããã
ãããæ¥æ¬ãå°ã£ãŠããã
ãšãã«ãå°æ¹Ÿã¯çã£å
ã«
æãå·®ã䌞ã¹ãŠãããã
æ¥æ¬ããã®ã¯ã¯ãã³æäŸ
ãå®çŸããã°ããã®æ©è¿
ãã«ãªãã æ¥å°å奜ã®é²
å±ã«ãšã£ãŠæ¥µããŠéèŠãª
ããšã ã æ¥å°ãä»ãæªæ¥
ãæãæºããæ©ãã§ãã å®åé¢è°å¡ã¯26æ¥æãã
ããã®è¯ãäºäŸã«ãªããããèªã£ãã
ããŠãããäžå€®é信瀟ããããã®èæ¯ã«ã¯ãäžåœæžã¿ã®äžåœã®ãäžæµ· ããããã¹ã»ã¢ããã äº å°éã§ã¯ãæ¥æ¬æ¿åºã1
éå¶ããæ¥æ¬èªãµã€ã å
񇜆
æ¿æš©ã®åœ±ãããã å»è¬ãããäžåœæ¬åãéŠ æå²¡çããäžçä¿å¥æ© 00äž
| ããã©ãŒã«ã¹å°æ¹Ÿãã«ããšããã
ããšã25æ¥ã®æ°èŠææè
æ¥ä»ã®å°çŽã«ãã ã§ã®è²©å£²ä»£çæš©ãèªåã2æ¥ãããªã³ã©ã€ã³åœ¢å°éã§ã¯ãè¡æ¹äžæè
ã®
ãã«ãªã ãã§ãªãå°é¢(WHO)ã®å¹Žæ¬¡ç·äŒ éããã1幎ã®å°æ¹Ÿæ±éš
ã¯302人ã§ã2~25æ¥ ãšã¯2æ¥ã«éããã¡ãæããŠãããªã©ã§ãŸã£ãããäžåœã®æåºãããå°é
ã«ãããŠäººã亡ããªã£ãäžå
æ°äž»é²æ©å
ã®ä»å
¥ïœ€ããªã³ãã㯠å察ãåããŠã®ãªããŒã ããã
ããšããã
äŒåã§ãã¯ã¯ãã³è³Œå
¥ã«ãå°æ¹Ÿãšã®å¥çŽãèŠéã£ã¶ãŒããŒåå ã¯èªãããä»åã®åããã©ãèŠbo
人å£çŽ2300äžäººã®ã€ããŠãç§ãã¡ã¯ãã€ãç¶æ
ã ãšããã
ãã¡ããããŸã§ã«è³Œå
¥ãã®ã¡ãŒã«ãŒãšã®äº€æžãã¯äžåœã«ãã劚害工äœãšäžåœã¯ãå°æ¹Ÿã®ã¯ã¯ãäžåœãå°æ¹Ÿã®äºæ
ãªãã£ã
ãã¯ã¯ãã³ã¯çŽ70äžåå ãŒå®äºããŠããããäžåœ ããã°ã ãäžåœããã¿ã³èª¿éã®åŠšå®³ãåŠå®ã㊠ã«è©³ããè©è«å®¶ã®ç³å¹³æ°
ãšãããã¯ã¯ãã³äžè¶³ãã®ä»å
¥ã«ããå¥çŽã§ããªãªããšæ¶æ(ãã)ãããŠããã
çž
ç³å¹³æ°ã決æã¯æ£çŸ©ãã®ãã®ãæ¥æ¬ã®åœçé«ãããäžãé«ãè©ã§ã
è¶
å
掟è°å¡é£çãæ¥è¯ æ°åã³ããã®æã蟌ã¿
ãè°å¡æè«äŒãã®ã¡ã³ããŒã«æåããŠããå°æ¹Ÿã ãããããªããæ¥æ¬æ¿ çµŠæ¯æŽãæ€èšããŠããããã®æã®åããçã®äŒç€Ÿ ãã¢ãã«ããã®ã¯ãŒã ã ã¢ãžã¢ææ°ã®ã芪
ã§ãããèªæ°å
ã®åç°æ¿ãã5æäžæ¬ä»¥éãå€ç°åºãå°æ¹Ÿãžã®ã¯ã¯ãã³äŸãšãç£çµæ°èã28æ¥æå åã ããã察å¿ã ãã¯ãã³ã§çŽ24åå忥ãã§ããå°æ¹Ÿã𿥿¬
京京
å
šé ã«ã©ãŒéЬäœåç
æ±äž
ã§å ±ãããæ¿åºã»èªæ°å
æ¥æ¬åœæ°ãžã®æ¥çš®ã¯ã(çŽ12å人å)ã18 ãšã®çµã¯ãã匷åºã«ãª
é¢ä¿è
ãæããã«ãããšç±³è£œè¬å€§æããã¡ã€ã¶æ³ä»¥äžã®æ¥çš®å¯Ÿè±¡è
ã®ã»ããäžåœå
񇜆
æ¿æš©ã®
ãããå®çŸããã°ãããŸãã®ã¯ã¯ãã³ãšã米補 ãŒå
šå¡åã確ä¿ããŠãæŽã«å¯ŸãããNOããçª
ãã圱é¿ã¯ãªãèŠéã ãä»ãããšããæå³ã§çŽ
æ¿åºå
ã§ã¯ãã¯ã¯ãã³æŽãããããšã ã瀟
å
±å賌å
¥ããŠéäžåœã«äŒã®äžã§ã®æ¥æ¬ã®åœçã
åé
ããåœéçæ çµã¿ é«ããã¢ãžã¢å€ªå¹³æŽå°å
ãCOVAX (ã³ããã¯ãã®å®å
šã«è³ããã®ã¯éé
ã¹)ããéããŠå°æ¹Ÿã«äŸããªãããšèªã£ãŠããã
ã·çµŠããæ¡ãæµ®äžããŠã
å¿
èŠãªäŸçµŠéãæäŸææ
ãªã©ãèãåã£ãããã§
詳现ãã€ãããæ©ããã°
æ¥æã«ãæäŸã®å®çŸãç®
æãã
ãç¬å æ¿çœ
æ¥æ¬
ãè
çŸ©åæ¿æš©ã¯ç·æ¥æ¯æŽãäžå¯æ¬ ãšå€æããã
ãšå°æ¹Ÿã¯ãããŸã§ãå€§èŠæš¡çœå®³ãªã©ã§çžäºã«å©ãåã£
ãŠãããäžåœã®è»äºçèŠæš©æ¡å€§ãé²ããªãããå°æ¹Ÿæ
ã¯ã¯ãã³ãæäŸããã
äºãã¯ãæ¥æ¬æäºãã«çŽçµããã
ã2é¢ã«é¢é£èšäºã
ã°ãæ¥å°ã®çµãã¯äžå±€æ·±ãŸãããã ã
ãã£ãããšè©±ããäžåœã®
ããã
AstraZeneca
ããã³ã³ã»ã¹ãããã©
æšå
EXCITING
ã© æ¥å°ã®çžäºæ¯æŽã®æŽå²
åé ã®æ±æ¥æ¬å€§éçœã
ãã§ã¯ãªããæšå¹Ž4æãæ°
åã³ããã®æææ¡å€§ã«äŒŽ
ããã¹ã¯äžè¶³ã®éã«ã¯ã
å°æ¹Ÿããå»ççšãã¹ã¯2
è±00äžæãéããã
2016幎ã®å°æ¹Ÿåéš)
ã¯äœ¿ã
SEME
AMUSE
SAFETY FIRST
æ¬æ¥çºå£²
DRY"
第156 5æ28æ¥çºè¡
599å·
é»åçã®ç³ã蟌ã¿ã¯WEBã§ãç£çµé»åçãã§æ€çŽ¢